Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
This article was originally published in PharmAsia News
MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted
You may also be interested in...
MUMBAI - Realizing the importance of developing inexpensive biotech treatments, India's Department of Biotechnology has for the first time invited proposals from Indian companies to work together on the development of biosimilar products
SINGAPORE - It may sound too idealistic but Israel Makov, Teva's former chief executive, believes the present drought of late-stage pipeline drugs can be filled if smaller companies doing research in "silos" share their specialized insights and form single entities to develop future drugs
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).